CH593275A5 - (15)-(Hetero) aryl prostaglandin analogues - with long-lasting prostaglandin-like activity - Google Patents

(15)-(Hetero) aryl prostaglandin analogues - with long-lasting prostaglandin-like activity

Info

Publication number
CH593275A5
CH593275A5 CH633877A CH633877A CH593275A5 CH 593275 A5 CH593275 A5 CH 593275A5 CH 633877 A CH633877 A CH 633877A CH 633877 A CH633877 A CH 633877A CH 593275 A5 CH593275 A5 CH 593275A5
Authority
CH
Switzerland
Prior art keywords
phenyl
alpha
prostaglandin
lower alkyl
naphthyl
Prior art date
Application number
CH633877A
Other languages
French (fr)
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Priority claimed from CH706076A external-priority patent/CH593963A5/xx
Publication of CH593275A5 publication Critical patent/CH593275A5/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D307/00Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/93Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems condensed with a ring other than six-membered
    • C07D307/935Not further condensed cyclopenta [b] furans or hydrogenated cyclopenta [b] furans
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D307/00Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/38Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D307/54Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D309/00Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D309/08Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D309/10Oxygen atoms
    • C07D309/12Oxygen atoms only hydrogen atoms and one oxygen atom directly attached to ring carbon atoms, e.g. tetrahydropyranyl ethers
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D317/00Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/44Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D317/46Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D317/48Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
    • C07D317/50Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to atoms of the carbocyclic ring
    • C07D317/60Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D333/00Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/06Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
    • C07D333/24Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6553Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having sulfur atoms, with or without selenium or tellurium atoms, as the only ring hetero atoms
    • C07F9/655345Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having sulfur atoms, with or without selenium or tellurium atoms, as the only ring hetero atoms the sulfur atom being part of a five-membered ring
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B63SHIPS OR OTHER WATERBORNE VESSELS; RELATED EQUIPMENT
    • B63BSHIPS OR OTHER WATERBORNE VESSELS; EQUIPMENT FOR SHIPPING 
    • B63B2211/00Applications
    • B63B2211/02Oceanography

Abstract

Cpds of formula (I): (where Ar is alpha- or beta-furyl, alpha- or beta-thienyl, alpha- or beta-naphthyl, phenyl, 3,4-dimethoxyphenyl, 3,4-methylenedioxyphenyl, 3,4,5-trimethoxyphenyl or phenyl monosubstd. by halogen, CF3, phenyl, lower alkyl or lower alkoxy, n = 0-5 but is 0 or 1 when A is phenyl, substd. phenyl or naphthyl; R is H, or lower alkyl; W is a single bond or a cis double bond; Z is a single bond or a trans double bond; M is O, -H or -OH ; N and L form a single bond or N is alpha-OH, and L is H, where M, N and L are selected to give the structure of an A, E or F series prostaglandin) and their 9 alpha, 11 alpha and 15 alpha lower alkanoyl, formyl and benzoyl esters and salts are prepd. by standard methods, the (CH2)nAr gp being introduced by reacting the corresp. aldehyde with Ar(CH2)nCOCH2 PO(OAlk)2 and reducing or alkylating the prodt. Cpds. (I) are the 15-aralkyl, analogues of the F,E, and A series prostaglandin and have the same activities with a longer lasting effect.

Description

  

  
 



   L'invention se rapporte à la préparation de nouvelles substances utiles, par exemple, comme produits de départ dans la synthèse de certains nouveaux homologues des prostaglandines naturelles.



   L'invention concerne un procédé de préparation d'un composé de formule développée:
EMI1.1     
 dans laquelle
Ar est un groupement a- ou   ss-furyle;    a- ou   ss-thiényle;    a- ou   ss-naphtyle;    phényle; 3,4-diméthoxyphényle; 3,4-méthylènedioxyphényle; 3,4,5-triméthoxyphényle; ou phényle monosubstitué dont ledit substituant est un atome d'halogène ou un groupement trifluorométhyle, phényle, alkyle inférieur ou alcoxy inférieur;   n n est un entier de O à 5 pourvu que quand Ar est un groupe-    ment phényle, phényle substitué ou naphtyle, n soit égal à O ou   à 1 ;   
R est un groupement alkyle inférieur;

   et
Q est un groupement p-biphénylcarbonyle, caractérisé en ce qu'on fait réagir un composé de formule   IIA   
EMI1.2     
 avec un agent d'alkylation inférieur pour obtenir un composé de formule   II    dans laquelle Ar, n et Q sont tels que définis précédemment et R est un groupement alkyle inférieur; et si on le désire, on traite un composé de formule III précédente dans laquelle Ar, n, Q et R sont tels que définis précédemment avec K2CO3 pour obtenir un composé de formule III dans laquelle Q est un atome d'hydrogène; et, si on le désire, on sépare les isomères 8a et   8ss.   



   Comme on voit dans le schéma A, on transforme l'énone 3 en un mélange d'alcools tertiaires 13 et 14 par réaction avec   l'alkyl4ithium    ou le réactif de Grignard approprié et on peut séparer les isomères 13 et 14 par chromatographie sur colonne ou chromatographie liquide sous pression élevée. Les transformations ultérieures de 14 sont indiquées sur le schéma B.



   La transformation 14   e   6 est une transestérification catalysée par une base dans laquelle le groupement protecteur pbi-phénylcarbonyle est éliminé. Ceci est effectué de façon la plus commode avec du carbonate de potassium dans un solvant qui est le méthanol ou un mélange de méthanol et de tétrahy   drofuranne. La transformation 6 e 7 nécessite la protection    des deux groupements hydroxyle libres avec un groupement protecteur qui est labile vis-à-vis des acides. Tout groupement suffisamment labile vis-à-vis des acides est satisfaisant; cependant le groupement le plus habituel est le groupement tétrahydropyranyle qui peut être introduit dans la molécule par traitement avec du dihydropyranne et un catalyseur acide dans un milieu anhydre. Le catalyseur est généralement l'acide ptoluènesulfonique.



  Schéma A
EMI1.3     
  
EMI2.1     
  
 Le schéma C illustre la synthèse de précurseurs en 13,14   dihydro-co-pentanorprostaglandines    substituées en 15.



   En outre, on peut réduire catalytiquement avec de l'hydrogène les composés 13 et 14 du schéma A respectivement en 20 et   20s.    L'étape à laquelle on réduit la double liaison n'est pas déterminante, et l'hydrogénation des composés 6 ou 7 du schéma B peut également fournir des intermédiaires utiles pour les homologues de 13,14-dihydro-prostaglandine de la présente invention. On peut effectuer cette réduction avec un catalyseur homogène comme le chlorure de tristriphénylphosphinerhodium ou avec un catalyseur hétérogène comme le platine, le palladium ou le rhodium.



   Schéma C
EMI3.1     

 Dans les modes opératoires précédents, où on désire une purification par chromatographie, les supports chromatographiques appropriés comprennent l'alumine neutre et le gel de silice, et on préfère généralement du gel de silice à 74-250 microns. On effectue de façon appropriée la chromatographie dans les solvants inertes vis-à-vis de la réaction comme l'éther, l'acétate d'éthyle, le benzène, le chloroforme, le chlorure de méthylène, le cyclohexane et le n-hexane, comme mieux illustré dans les exemples annexés.



   Préparation y-Lactone de l'acide   2-[3a-p-phénylbenzoyloxy-5a-    hydroxy-2   ss-(3-oxo-4-phényl-trans-    1-butèn-1 -yl)cyclopent-la-yl]acétique (3a):
 Méthode A
 On traite du 2-oxo-3-phénylpropylphosphonate de diméthyle (2a) (3,4 g, 14,2 mmoles) dans 200 ml d'éther anhydre, avec 5,0   ml    (12,5 mmoles) d'une solution 2,5 M de n-butyllithium dans du nexane (Alfa Inorganics, Inc.) sous atmosphère d'azote sec à la température ambiante. Après 5 minutes d'agitation, on ajoute 400   ml    supplémentaires d'éther anhydre, puis 3,85 g (11 mmoles) de la y-lactone de l'acide 2-[3a-p-phénylbenzoyloxy-5 a-hydroxy-2   P-formylcyclopentan- 1      a-yl]acétique    en une fois et 50   ml    d'éther anhydre.

  Après 35 minutes, on arrête la réaction du mélange avec 5   ml    d'acide acétique glacial, on lave le mélange avec 100   ml    d'une solution saturée de bicarbonate de sodium (4 X), 100   ml    d'eau (2 x), 100   ml    d'une saumure saturée (1 x), on le sèche (MgS04) et on l'évapore, ce qui donne 2,908 g   (57%)    de la y-lactone de l'acide 2-[3 a-p-phénylbenzoyloxy-5 a-hydroxy-2   ss-(3-oxo-4-    phényl-trans-1-butèn-1-yl)cyclopent-la-yl]acétique (3a) sous forme d'une mousse après chromatographie sur colonne (gel de silice, Baker, 74-250 microns), p. f.   107-108    (éther).



   Méthode B
 On traite du   2-oxo-3-phénylpropylphosphonate    de diméthyle (2a) (2,9 g, 12 mmoles) dans 20   ml    de diméthoxyéthane anhydre, avec 4,7   ml    (11 mmoles) d'une solution 2,34 M de nbutyllithium dans du n-hexane (Alfa Inorganics, Inc.) sous atmosphère d'azote sec à la température ambiante. Après 40 minutes d'agitation, on ajoute en une fois 3,5 g (10 mmoles) de la y-lactone de l'acide 2-[3a-p-phénylbenzoyloxy-5a   hydroxy-2P-formylcyclopentan-l a-yl]acétique,    puis 15   ml    de 1,2-diméthoxy-éthane anhydre.

  Après 30 minutes, on arrête la réaction du mélange avec 1   ml    d'acide acétique glacial, on filtre le mélange, on le lave avec 20   ml    d'une solution saturée de bicarbonate de sodium (2 x), 20   ml    d'une saumure saturée (1 x ), on le sèche   (Na2SO4)    et on l'évapore, ce qui donne 2 g (43 %) de la y-lactone de l'acide 2-[3 a-p-phénylbenzoyloxy5 a-hydroxy-2   ss-(3-oxo-4-phényl-trans-      1-butèn-1 -yl)cyclo-    pent-la-yl]acétique (3a) sous forme d'une mousse après chromatographie sur colonne (gel de silice, Baker, 74-250 microns).

 

   Le spectre IR (CHCl3) du produit (3a) présente des bandes d'absorption à 1775   cm-1 (forte),    1715 cm-1 (forte), 1675 cm-1 (moyenne) et 1630   cm-l    (moyenne) attribuables aux groupements carbonyle et à 973   cm-l    pour la double liaison trans. Le spectre RMN (CDCl3) présente un multiplet à 7,23-8,18 6 (9H) pour le groupement p-biphényle, un doublet de doublets centré à 6,75 6 (1H, J = 16 Hz) et un doublet centré à 6,27 6 (1H, J = 16 Hz) pour les protons oléfiniques, un singulet large à 7,20   Ï    (5H) pour
EMI3.2     
 un singulet à 3,84 6 (2H) pour
EMI3.3     
 et des multiplets à 4,90-5,50 6 (2H) et 2,21-3,07 6 (6H) pour le reste des protons.



   Exemple y-Lactone de l'acide 2-[3a-p-phénylbenzoyloxy-5a   hydroxy-2 ss-(3 a-hydroxy-3 ss-méthyl-4-phényl-trans- 1 -     butèn-1-yl)cyclopent-1 a-yl]acétique (13a) et y-lactone de l'acide 2-[3a-p-phénylbenzoyloxy-5a   hydroxy-2 8-(3    a-hydroxy-3   a-méthyl-4-phényl-trans-1-      butèn-1-yl)cyclopent-la-yl]acétique    (14a)
 A une solution de 2908 mg (6,2 mmoles) de la y-lactone de l'acide 2-[3   a-p-phényl-benzoyloxy-5    a-hydroxy-2   B-(3-oxo-4-      phényl-trans-1-butèn-1-yl)cyclopent-1 a-yljacétique    (3a) dans 26 ml d'éther anhydre et 20 ml de tétrahydrofuranne (distillé à partir de l'hydrure d'aluminium et de lithium) sous atmosphère d'azote sec à   -78 ,    on ajoute goutte à goutte 6,8 ml d'une solution 0,92 M de 

   méthyllithium dans l'éther (Alfa). Après avoir agité à   -78     pendant 15 minutes, on arrête la réaction par addition goutte à goutte d'acide acétique glacial jusqu'à ce que le pH de la réaction soit approximativement 7. Puis on dilue le mélange avec du chlorure de méthylène et on lave la solution organique diluée avec de l'eau (1 X) et avec une saumure saturée (1 x), on la sèche (sulfate de magnésium anhydre), et on la concentre pour obtenir les alcools épimères.



   On purifie le produit brut par chromatographie sur colonne sur 108 g de gel de silice (Baker  Analyzed  Reagent 74-250 microns) en utilisant comme éluant un mélange de benzène et d'acétate d'éthyle, pour obtenir la   y.lactone    de l'acide 2-[3 ap-phényl-benzoyloxy-5 a-hydroxy-2   ss-(3    a-hydroxy-3   ss-méthyl-      4-phényl-trans-1-butèn-1-yl)cyclopent-1    a-yl]acétique   (1 3a)    et la y-lactone de l'acide   2-[3a-p-phénylbenzoyloxy-5a-hydroxy-    2   ss-(3      I3-hydroxy-3      Åa-méthyl-4-phényl-trans-      1-butèn-1-yl)cy-      clopent-la-yl]acétique    (14a).

 

   On peut transformer cette substance (14a) en   15ss-méthyl-      16-phényl-o-tétranorprostaglandines    des séries A, E et F.



   On peut également préparer d'autres dérivés substitués par des groupements alkyle inférieur du type (14a) en remplaçant le méthyllithium par l'alkyllithium approprié dans le mode opératoire précédent. Ces dérivés sont appropriés pour la transformation en 15-(alkyl   inférieur)-16-phényl-oa-tétranor-    prostaglandines des séries A, E et F. 



  
 



   The invention relates to the preparation of novel substances useful, for example, as starting materials in the synthesis of certain novel homologues of natural prostaglandins.



   The invention relates to a process for preparing a compound of structural formula:
EMI1.1
 in which
Ar is an a- or ss-furyl group; a- or ss-thienyl; a- or ss-naphthyl; phenyl; 3,4-dimethoxyphenyl; 3,4-methylenedioxyphenyl; 3,4,5-trimethoxyphenyl; or monosubstituted phenyl in which said substituent is a halogen atom or a trifluoromethyl, phenyl, lower alkyl or lower alkoxy group; n n is an integer of 0 to 5 provided that when Ar is phenyl, substituted phenyl or naphthyl, n is 0 or 1;
R is a lower alkyl group;

   and
Q is a p-biphenylcarbonyl group, characterized in that a compound of formula IIA is reacted
EMI1.2
 with a lower alkylating agent to obtain a compound of formula II in which Ar, n and Q are as defined above and R is a lower alkyl group; and if desired, treating a compound of the preceding formula III in which Ar, n, Q and R are as defined above with K2CO3 to obtain a compound of formula III in which Q is a hydrogen atom; and, if desired, separating the 8a and 8ss isomers.



   As seen in Scheme A, enone 3 is converted into a mixture of tertiary alcohols 13 and 14 by reaction with alkyl lithium or the appropriate Grignard reagent and the 13 and 14 isomers can be separated by column chromatography or high pressure liquid chromatography. Subsequent transformations of 14 are shown in figure B.



   The 14 e 6 transformation is a base catalyzed transesterification in which the pbi-phenylcarbonyl protecting group is removed. This is most conveniently carried out with potassium carbonate in a solvent which is methanol or a mixture of methanol and tetrahydrofuran. The 6 e 7 transformation requires the protection of the two free hydroxyl groups with a protecting group which is labile towards acids. Any group which is sufficiently labile with respect to acids is satisfactory; however the most usual group is the tetrahydropyranyl group which can be introduced into the molecule by treatment with dihydropyran and an acid catalyst in an anhydrous medium. The catalyst is generally ptoluenesulfonic acid.



  Diagram A
EMI1.3
  
EMI2.1
  
 Scheme C illustrates the synthesis of precursors in 13,14 dihydro-co-pentanorprostaglandins substituted in 15.



   In addition, compounds 13 and 14 of scheme A can be catalytically reduced with hydrogen in 20 and 20s, respectively. The step at which the double bond is reduced is not critical, and the hydrogenation of compounds 6 or 7 of Scheme B may also provide useful intermediates for the 13,14-dihydro-prostaglandin homologues of the present invention. This reduction can be carried out with a homogeneous catalyst such as tristriphenylphosphinerhodium chloride or with a heterogeneous catalyst such as platinum, palladium or rhodium.



   Diagram C
EMI3.1

 In the foregoing procedures, where purification by chromatography is desired, suitable chromatographic media include neutral alumina and silica gel, and 74-250 micron silica gel is generally preferred. The chromatography is suitably carried out in solvents which are inert with respect to the reaction such as ether, ethyl acetate, benzene, chloroform, methylene chloride, cyclohexane and n-hexane, as best illustrated in the attached examples.



   2- [3a-p-phenylbenzoyloxy-5a- hydroxy-2 ss- (3-oxo-4-phenyl-trans-1-buten-1 -yl) cyclopent-la-yl] acetic acid y-Lactone preparation (3a):
 Method A
 Dimethyl 2-oxo-3-phenylpropylphosphonate (2a) (3.4 g, 14.2 mmol) in 200 ml of anhydrous ether is treated with 5.0 ml (12.5 mmol) of solution 2 , 5 M n-butyllithium in nexane (Alfa Inorganics, Inc.) under a dry nitrogen atmosphere at room temperature. After 5 minutes of stirring, an additional 400 ml of anhydrous ether is added, followed by 3.85 g (11 mmol) of the 2- [3a-p-phenylbenzoyloxy-5a-hydroxy-2 acid y-lactone. P-formylcyclopentan-1α-yl] acetic all at once and 50 ml of anhydrous ether.

  After 35 minutes, the reaction of the mixture is stopped with 5 ml of glacial acetic acid, the mixture is washed with 100 ml of a saturated solution of sodium bicarbonate (4 X), 100 ml of water (2 x), 100 mL of saturated brine (1x), dried (MgSO4) and evaporated to give 2.908 g (57%) of 2- [3 ap-phenylbenzoyloxy- acid y-lactone. 5 a-hydroxy-2 ss- (3-oxo-4-phenyl-trans-1-buten-1-yl) cyclopent-la-yl] acetic (3a) in the form of a foam after column chromatography (gel of silica, Baker, 74-250 microns), p. f. 107-108 (ether).



   Method B
 Dimethyl 2-oxo-3-phenylpropylphosphonate (2a) (2.9 g, 12 mmol) in 20 ml of anhydrous dimethoxyethane is treated with 4.7 ml (11 mmol) of a 2.34 M solution of nbutyllithium in n-hexane (Alfa Inorganics, Inc.) under a dry nitrogen atmosphere at room temperature. After 40 minutes of stirring, 3.5 g (10 mmol) of the γ-lactone of 2- [3a-p-phenylbenzoyloxy-5a hydroxy-2P-formylcyclopentan-1 a-yl] are added all at once. acetic, then 15 ml of anhydrous 1,2-dimethoxy-ethane.

  After 30 minutes, the reaction of the mixture is stopped with 1 ml of glacial acetic acid, the mixture is filtered, washed with 20 ml of a saturated solution of sodium bicarbonate (2 x), 20 ml of a brine. saturated (1x), dried (Na2SO4) and evaporated to give 2 g (43%) of 2- [3 ap-phenylbenzoyloxy5 a-hydroxy-2 ss- acid y-lactone (3-oxo-4-phenyl-trans-1-buten-1 -yl) cyclopent-la-yl] acetic (3a) in the form of a foam after column chromatography (silica gel, Baker, 74- 250 microns).

 

   The IR spectrum (CHCl3) of product (3a) shows attributable absorption bands at 1775 cm-1 (strong), 1715 cm-1 (strong), 1675 cm-1 (average) and 1630 cm-l (average) to carbonyl groups and to 973 cm-1 for the trans double bond. The NMR spectrum (CDCl3) shows a multiplet at 7.23-8.18 6 (9H) for the p-biphenyl group, a doublet of doublets centered at 6.75 6 (1H, J = 16 Hz) and a centered doublet at 6.27 6 (1H, J = 16 Hz) for olefinic protons, a broad singlet at 7.20 Ï (5H) for
EMI3.2
 a singlet at 3.84 6 (2H) for
EMI3.3
 and multiplets at 4.90-5.50 6 (2H) and 2.21-3.07 6 (6H) for the rest of the protons.



   Example y-2- [3a-p-phenylbenzoyloxy-5a hydroxy-2 ss- (3 a-hydroxy-3 ss-methyl-4-phenyl-trans- 1 - buten-1-yl) cyclopent- acid y-lactone 2- [3a-p-phenylbenzoyloxy-5a hydroxy-2 8- (3 a-hydroxy-3 a-methyl-4-phenyl-trans-1 α-yl] acetic acid (13a) and y-lactone - buten-1-yl) cyclopent-la-yl] acetic (14a)
 Has a solution of 2908 mg (6.2 mmol) of 2- [3 ap-phenyl-benzoyloxy-5 a-hydroxy-2 B- (3-oxo-4-phenyl-trans- acid y-lactone) 1-buten-1-yl) cyclopent-1 a-yljacetic (3a) in 26 ml of anhydrous ether and 20 ml of tetrahydrofuran (distilled from lithium aluminum hydride) under a dry nitrogen atmosphere to -78, 6.8 ml of a 0.92 M solution of

   methyllithium in ether (Alfa). After stirring at -78 for 15 minutes, the reaction is quenched by the dropwise addition of glacial acetic acid until the reaction pH is approximately 7. Then the mixture is diluted with methylene chloride and the mixture is diluted. Wash the dilute organic solution with water (1 X) and with saturated brine (1 x), dry (anhydrous magnesium sulfate), and concentrate to obtain the epimeric alcohols.



   The crude product is purified by column chromatography on 108 g of silica gel (Baker Analyzed Reagent 74-250 microns) using a mixture of benzene and ethyl acetate as eluent, to obtain the y.lactone of the. 2- [3 ap-phenyl-benzoyloxy-5 a-hydroxy-2 ss- (3 a-hydroxy-3 ss-methyl-4-phenyl-trans-1-buten-1-yl) cyclopent-1 a-yl acid ] acetic acid (1 3a) and 2- [3a-p-phenylbenzoyloxy-5a-hydroxy- 2 ss- (3 I3-hydroxy-3 Åa-methyl-4-phenyl-trans- 1- acid y-lactone buten-1-yl) cyclopent-la-yl] acetic acid (14a).

 

   This substance (14a) can be converted into 15ss-methyl-16-phenyl-o-tetranorprostaglandins of series A, E and F.



   It is also possible to prepare other derivatives substituted with lower alkyl groups of the type (14a) by replacing the methyllithium with the appropriate alkylithium in the preceding procedure. These derivatives are suitable for conversion to 15- (lower alkyl) -16-phenyl-oa-tetranorprostaglandins of series A, E and F.

 

Claims (1)

REVENDICATION CLAIM Procédé de préparation d'un composé de formule EMI4.1 dans laquelle Ar représente un radical a- ou B-furyle, a- ou thiényle, a- ou B-naphtyle, phényle, 3,4-diméthoxyphényle, 3,4 méthylènedioxyphényle, 3,4,5-triméthoxyphényle, ou phényle monosubstitué par halogène, trifluorométhyle, phényle, alkyle inférieur ou alcoxy inférieur, n est un nombre entier de 0 à 5 pourvu que, quand Ar est un groupe phényle, phényle substitué ou naphtyle, n soit égal à 0 ou 1; R est un groupe alkyle inférieur, et Q est un radical p-biphénylcarbonyle, caractérisé en ce qu'on fait réagir un composé de formule EMI4.2 avec un agent d'alkylation inférieur. Process for preparing a compound of the formula EMI4.1 in which Ar represents an a- or B-furyl, a- or thienyl, a- or B-naphthyl, phenyl, 3,4-dimethoxyphenyl, 3,4-methylenedioxyphenyl, 3,4,5-trimethoxyphenyl, or phenyl monosubstituted by halogen, trifluoromethyl, phenyl, lower alkyl or lower alkoxy, n is an integer from 0 to 5 provided that when Ar is phenyl, substituted phenyl or naphthyl, n is 0 or 1; R is a lower alkyl group, and Q is a p-biphenylcarbonyl radical, characterized in that a compound of formula EMI4.2 with a lower alkylating agent. SOUS-REVENDICATIONS 1. Procédé selon la revendication, caractérisé en ce qu'on soumet un composé obtenu à l'action hydrolytique de K2CO3 pour remplacer le radical Q par un atome d'hydrogène. SUB-CLAIMS 1. Method according to claim, characterized in that subjects a compound obtained to the hydrolytic action of K2CO3 to replace the radical Q by a hydrogen atom. 2. Procédé selon la revendication, caractérisé en ce qu'on sépare les isomères 8a et 8ss d'un mélange d'épimères obtenu. 2. Method according to claim, characterized in that the 8a and 8ss isomers are separated from a mixture of epimers obtained.
CH633877A 1972-07-13 1973-07-12 (15)-(Hetero) aryl prostaglandin analogues - with long-lasting prostaglandin-like activity CH593275A5 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US27122072A 1972-07-13 1972-07-13
CH706076A CH593963A5 (en) 1972-07-13 1973-07-12

Publications (1)

Publication Number Publication Date
CH593275A5 true CH593275A5 (en) 1977-11-30

Family

ID=25700666

Family Applications (1)

Application Number Title Priority Date Filing Date
CH633877A CH593275A5 (en) 1972-07-13 1973-07-12 (15)-(Hetero) aryl prostaglandin analogues - with long-lasting prostaglandin-like activity

Country Status (1)

Country Link
CH (1) CH593275A5 (en)

Similar Documents

Publication Publication Date Title
JP4267702B2 (en) Total synthesis of antitumor acylfulvenes
KR101986966B1 (en) How to make Vera Frost
JP3568219B2 (en) Preparation of 19-norvitamin D compound
JPS61122292A (en) Production of novel carbacycline intermediate
AT367747B (en) METHOD FOR PRODUCING OPTICALLY ACTIVE OR RACEMIC PROSTAGLANDINS AND THEIR SALTS
White et al. Novel synthesis of the tricyclic nucleus of verrucarol
US4345984A (en) Novel prostaglandin analogues and process for making same
CA1142532A (en) Aldol derivatives and production thereof
CH637359A5 (en) 8-EXO-HYDROXYMETHYL-ENDO-TRICYCLO (5.2.1.O (2,6)) - DECANE DERIVATIVES.
CH593275A5 (en) (15)-(Hetero) aryl prostaglandin analogues - with long-lasting prostaglandin-like activity
US4024181A (en) Analogues of prostanoic acids
US4958037A (en) Precursors and synthesis of methyl-9-oxo-11α, 16-dihydroxy-16-vinyl-5-cis-13-trans-prostadienoates
EP0105267A1 (en) Method for the preparation of intermediary compounds of carbacyclin.
US5191125A (en) Procedure for the preparation of bicyclo [3.2.0]hept-2-en-7-ones
KR840001569B1 (en) Process for the preparation of prostaglandine derivatives of 2-pge2 2-pgf2 series
EP0008077B1 (en) Prostaglandin derivatives with a delta-2-pgf2 structure or a delta-2-pge2 structure, process for their preparation and their use as medicaments
US4122093A (en) Process for preparing a lactone
EP0213313A2 (en) Precursors and synthesis of methyl-9-oxo-11 alpha, 16-dihydroxy-16-vinyl-5-cis-13-trans prostadienoates
JP3558681B2 (en) Hexahydroindane derivative
JP2860506B2 (en) Halogenoallyl alcohol derivatives
JPH10251183A (en) Synthetic intermediate useful for synthesizing a-ring moiety of vitamin d derivative, its production and usage thereof
US4496759A (en) Novel prostaglandin analogues and process for making same
Walkup et al. Preparation of 2-(Tetrahydrofuran-2′-YL)-l, 4-Pentadienes From γ-Allenyl Alcohols via Oxymercuration Followed by Palladium (II)-Medlated all Ylation
JP2991774B2 (en) Novel synthetic method of propargyl alcohol and use of said alcohol for producing prostaglandin precursor
JP2788333B2 (en) Method for producing cyclopentanols

Legal Events

Date Code Title Description
PL Patent ceased